

Curriculum Vitae
Justin P. Favaro, MD, PhD

Practice Address:

President, MD Oncology Specialists of Charlotte
Oncologist 2630 E 7th Street, Suite 210
July, 2006-Present Charlotte, NC 28204
jfavaro@oncologycharlotte.com

Site Affiliations:

2017-Present DJL Clinical Research, PLLC
10370 Park Road, Suite 200
Charlotte, NC 28210

Education:

1988-1992 Bachelor of Science – Microbiology
Clemson University
Clemson, South Carolina

1992-2000 Doctor of Medicine
1992-2000 Doctor of Philosophy
Medical University of South Carolina
Charleston, South Carolina

2000-2003 Internship/Residency
University of Texas, Southwestern
Dallas, Texas

2003-2006 Hematology/Oncology Fellowship
Duke University Medical Center
Durham, North Carolina

Certifications:

2003 – 2013 Board Certification in Internal Medicine
2007 – Present Board Certification in Medical Oncology
2015 – Present Board Certification in Hematology

Professional Organizations:

1998 President, MUSC student chapter of the American Medical Association
2005 – Present American Society of Clinical Oncology
2008 – 2011 Community Oncology Alliance, Board Member
2008 – Present Community Oncology Alliance, Member
2014 – Present Blue Cross and Blue Shield of North Carolina P and T committee
2006 – Present North Carolina Oncology Association, member
2016 – Present President, North Carolina Oncology Association

Community:

2017 – Present Susan G Komen Pink Tie Guy

Honors and Awards:

Alpha Omega Alpha Honor society
Charlotte Magazine Top Doctors list 2013, 2014, 2015, 2017

Major Meeting Activities:

"Different Localization of Cytoplasmic HIV RNA's in the Presence and Absence of Rev"
Retroviruses. Oral Presentation. 1997. Cold Spring Harbor, NY.

"Construct and Cell Type Dependent Differences in HIV-1 Gene Regulation"
Eastern Student Research Forum. 1997. Miami, FL.

"Retroviral Packaging of an Anti-HIV Gene"
National Student Research Forum. 1995. Galveston, TX.

"Regulation of HIV-1 Protease Activity and Cytotoxicity"
2nd National Conference on Human Retroviruses and Related Infections. Poster Presentation. 1995.
Washington, DC.

"Scientific Implications of Somatic Cell Nuclear Transfer Technology"
American Medical Association Meeting. 1998. Chicago, IL.
American Medical Association Meeting. 1998. Honolulu, Hawaii

"Phase 1 Dose Escalation, Pharmacokinetic and Biomarker Study of Imatinib Mesylate (Gleevec/STI571)
Plus Capecitabine (Xeloda) in Advanced Solid Tumor Malignancies"
American Society of Clinical Oncology. Poster. 2006. Atlanta, GA.

Publications:

Qin L, Chavin KD, Ding Y, Woodward JE, **Favaro JP**, Lin J, Bromberg JS
"Gene Transfer for Transplantation. Prolongation of Allograft Survival with Transforming Growth Factor-
beta 1"
Annals of Surgery. 1994 Oct; 220(4):508-18; discussion 518-9

Qin L, Chavin KD, Ding Y, **Favaro JP**, Woodward JE, Lin J, Tahara H, Robbins P, Shaked A, Ho DY, et al.
"Multiple Vectors effectively Achieve Gene Transfer in a Murine Cardiac Transplantation Model.
Immunosuppression with TGF-beta 1 or vIL-10"
Transplantation. 1995 Mar 27; 59(6):809-16

Qin L, Chavin KD, Ding Y, Tahara H, **Favaro JP**, Woodward JE, Suzuki T, Robbins PD, Lotze MT, Bromberg
JS
"Retrovirus-Mediated Transfer of Viral IL-10 Gene Prolongs Murine Cardiac Allograft Survival"
Journal of Immunology. 1996 Mar 15; 156(6):2326-23

Borg KT, **Favaro JP**, Arrigo SJ
"Involvement of Human Immunodeficiency Virus Type-1 Splice in the Cytoplasmic Accumulation of Viral
RNA"
Virology. 1997 Sep 15; 236(1):95-103

Favaro JP and Arrigo SJ
"Construct and Cell Type Dependent Differences in HIV-1 Gene Regulation"
McGill Journal of Medicine. Spring/Summer 1997

Curriculum Vitae
Justin P. Favaro, MD, PhD

PH.D. Dissertation

Justin P. Favaro.

“Role of Rev in Determining the Fate of Human Immunodeficiency Virus-1 RNA”
1998

Favaro JP, Maldarelli F, Arrigo SJ, Schmidt MG.

“Effect of Rev on the Cytoplasmic Localization of Intron-Containing Human Immunodeficiency Virus Type 1 RNA”

Virology. 1998 Sep 30; 249(2):286-96

Favaro JP, Borg KT, Arrigo SJ, Schmidt MG.

“Effect of Rev on the Intranuclear Localization of HIV-1 Unspliced RNA”

Virology. 1998 Sep 30; 249(2):286-96

Borg KT, **Favaro JP**, Arrigo SJ, Schmidt MG

“Activation of a Cryptic Splice Donor in Human Immunodeficiency Virus Type-1”

J Biomed Sci. 1999 Jan; 6(1):45-52

Favaro JP, Wiley K, Blobe GC.

“Activin Receptor Like Kinase-1.”

AfCS-Nature Molecule Pages (2005). (doi:10.1038/mp.a000254.01)

Favaro JP and George Daniel J

“Targeted Therapy in Renal Cell Carcinoma”

Expert Opinion on Investigational Drugs. 2005 Oct: 14(10)1251-8

Hurwitz H, **Favaro J**, and Honeycutt W.

“Treatment with Bevacizumab, 5-Fluorouracil, and Leucovorin for Patients with Metastatic Colorectal Cancer”

The American Journal of Oncology Review. 2005 Sept: 4(9) Supplement 12:16-17.

“A Phase I Dose-Escalation Study of Imatinib Mesylate (Gleevec/STI571) Plus Capecitabine (Xeloda) in Advanced Solid Tumors”

Anticancer Res. 2010 Apr; 30(4):1251-6

Hurwitz HI, Honeycutt W, Haley S, **Favaro J**.

“Long-Term Treatment with Bevacizumab for Patients with Metastatic Colorectal Cancer: Case Report.”

Clin Colorectal Cancer. 2006 May; 6(1):66-9

Letter to the editor, coauthor, Charlotte News and Observer.

“Cancer Patients Could be Hurt, We Fear by Health Care Reform”

August 19, 2010.

Letter to the editor, Wall Street Journal.

Response to the article “In Treating Cancer, Insurer Tries New Way to Pay Docs”

October 21, 2010

Dugan E, Truax R, Meadows KL, Nixon AB, Petros WP, **Favaro J**, Fernando NH, Morse MA, Blobe GC, Hurwitz HI

Curriculum Vitae
Justin P. Favaro, MD, PhD

Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith Hopkins, Gretchen G. Kimmick, **Justin Favaro**, Erika Hamilton, Renee A. Welch, Sarah Bacus, and Kimberly Blackwell.

“Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing”
Clin Cancer Res. September 15, 2011 17; 6061

Mary Kay Asperheim and **Justin Favaro**.

“Introduction to Pharmacology”

Twelfth Edition. 2012

Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, **Favaro J**, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI.

“A Phase II Study of Capecitabine, Oxaliplatin and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas.”

Oncologist. 2013; 18(3):271-2. doi: 10.1634/theoncologist.2012-0404. Epub 2013 Mar 13

Lyudmila A Bazhenova, J Graeme Hodgson, Corey J Langer, George R Simon, Scott N Gettinger, Sai-Hong Ignatius Ou, Karen L Reckamp, Howard L West, Alberto A Chiappori, Han A Koh, Julian R Molina, Alice T Shaw, Jyoti D Patel, **Justin P Favaro**, Jeff Haney, William Reichmann, David Kerstein, Victor M Rivera, D Ross Camidge.

“Activity of Brigatinib in Crizotinib-Resistant ALK+ NSCLC Patients According to ALK Plasma Mutation Status.”

Presented at the 53rd Annual Meeting of the American Society of Clinical Oncology Chicago, Illinois, June 2–6, 2017

P Ryan¹, A McBride², D Ray³, S Pulgar³, RA Ramirez¹, E Elquza², **JP Favaro**⁴ and G Dranitsaris⁵

“Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis”

Journal of Oncology Pharmacy Practice. Received: 28 November 2018; Revised: 4 March 2019; Accepted: 4 March 2019

Clinical Research:

Principal Investigator – ACOSOG Z1071 Protocol: A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis

Principal Investigator – ACOSOG Z9001 Protocol: A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) versus Placebo in Patients following the resection of Primary Gastrointestinal Stromal Tumor (GIST), Including Amendment 1 and 2, dated 11/1/03

Principal Investigator – Alliance A031201 Protocol: Prostate--CRPC, minimally or asymptomatic, progressing

Principal Investigator – Alliance A081105 Protocol: Randomized double blind placebo controlled study of Erlotinib or placebo in patients with completely resected epidermal growth factor receptor mutant NSCLC

Curriculum Vitae
Justin P. Favaro, MD, PhD

Principal Investigator – Alliance A151216 Protocol: Alchemist--stage 1B-IIIa resected: biology study looking for ALK&EGFR

Principal Investigator – Alliance A211201 Protocol: Change in Mammographic Density on Metformin: A Companion Study to NCIC CTG MA.32

Principal Investigator – Alliance EAY131 Protocol: Molecular analysis for therapy choice (MATCH)

Principal Investigator – Alliance A221102 Protocol: Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias

Principal Investigator – Alliance N1048 Protocol: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Principal Investigator – Alliance N107C Protocol: A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

Principal Investigator – CALGB 30610 Protocol: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

Principal Investigator – CALGB 40603 Protocol: Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor / HER2-Negative Resectable Breast Cancer

Principal Investigator – CALGB 49907 Protocol: A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), versus Capecitabine in Women 65 Years and Older with Node Positive or High - Risk Node

Principal Investigator – CALGB 50303 Protocol: Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas, Including Updates 1-12

Principal Investigator – CALGB 50801 Protocol: A Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)

Principal Investigator – CALGB 80701 Protocol: Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

Principal Investigator – CALGB 80803 Protocol: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer

Curriculum Vitae
Justin P. Favaro, MD, PhD

Principal Investigator – CALGB 500103 Protocol: Phase III Randomized Study of Four Weeks of High Dose IFN-Alpha2b in Stage T3-T4 or N1 (microscopic) Melanoma, including addendum #1,2,3,5 inclusive dated 3/04

Principal Investigator – CCCWFU 98213 Protocol: Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)

Principal Investigator – CTSU/CCTG MA.32 Protocol: A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer, protocol version 2010-Apr-09

Principal Investigator – DCP-001 Protocol: Collect information to understand cancer health disparities and clinical trial accrual

Principal Investigator – ECOG E1A06 Protocol: An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide versus Melphalan, Prednisone and Lenalidomide in Newly Diagnosed Myeloma Patients Who Are Not Candidates for High-Dose Therapy

Principal Investigator – ECOG E4512 Protocol: A phase III double-blind trial for surgically resected early stage non-small cell lung cancer: Crizotinib vs placebo for patients with tumors harboring the Anaplastic lymphoma Kinase (ALK) fusion protein

Principal Investigator – ECOG E5103 Protocol: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

Principal Investigator – ECOG E5202 Protocol: A Randomized Phase III Study comparing 5-FU, Leucovorin and Oxaliplatin vs. 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

Principal Investigator – ECOG E5508 Protocol: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Principal Investigator – ECOG EA5142 Protocol: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)

Principal Investigator – ECOG PACCT-1 Protocol: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial: Including Amendment #1.

Principal Investigator – NRG BR003 Protocol: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Principal Investigator – NRG HN002 Protocol: Testing less intensive treatment for selected low-risk patients with oropharyngeal cancer

Curriculum Vitae
Justin P. Favaro, MD, PhD

Principal Investigator – NSABP B-31 Protocol: Chemotherapy Treatment with or without Herceptin for Breast Cancer Patients who have Positive Axillary Nodes and Tumors that Overexpress HER2., Including Amendment #1.

Principal Investigator – NSABP B-35 Protocol: A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma In Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy

Principal Investigator – NSABP MPR-1 Protocol: The NSABP Patient Registry and Biospecimen Profiling Repository

Principal Investigator – NSABP B-38 Protocol: A Phase III, Adjuvant Trial comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC - P); DD AC followed b

Principal Investigator – NSABP B-46-I Protocol: NSABP B-46-I/USOR 07132 A Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Principal Investigator – NSABP B-47 Protocol: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Principal Investigator – NSABP B-49 Protocol: A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Principal Investigator – NSABP B-51 Protocol: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axill

Principal Investigator – RTOG R0413/B-39 Protocol: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer.

Principal Investigator – RTOG R0436 Protocol: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery

Principal Investigator – RTOG R0517 Protocol: Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer

Principal Investigator – RTOG R0621 Protocol: Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial

Principal Investigator – RTOG R0522 Protocol: A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin and Cetuximab (C225)(followed by Surgery for Selected Patients) for Stage III or IV Head and Neck Carcinoma, including update

Principal Investigator – RTOG R0534 Protocol: A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy

Principal Investigator – RTOG R0848 Protocol: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

Principal Investigator – RTOG R1016 Protocol: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer, Includes: 6/9/11 Update

Principal Investigator – RTOG R1203 Protocol: A Randomized Phase III Study of Standard Vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)

Principal Investigator – RTOG R96-01 Protocol: A Phase III Trial of Radiation Therapy With or Without Casodex In Patients with PSA Elevation following Radical Prostatectomy for pT3N0 Carcinoma of the Prostate, including revisions 1-3.

Principal Investigator – SWOG JMA17 Protocol: A Phase III Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen NCIC CTG Intergroup Study. SWOG JMA.17.Including Revisions #1 and #2.

Principal Investigator – SWOG S0702 Protocol: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patient with Bone Metastases Starting Zoledronic Acid Treatment – Includes Revision #1

Principal Investigator – SWOG S0713 Protocol: A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer

Principal Investigator – SWOG S0777 Protocol: Randomized Phase III Trial of CC-5013 (Lenalidomide) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma Without an Intent for Im

Principal Investigator – SWOG S0812 Protocol: A Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer, Phase IIB, Including revisions 1-4

Principal Investigator – SWOG S0820 Protocol: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III

Curriculum Vitae
Justin P. Favaro, MD, PhD

Principal Investigator – SWOG S1007 Protocol: A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less, Version date 6/4/2012

Principal Investigator – SWOG S1320 Protocol: Testing two different treatment schedules of dabrafenib and trametinib for skin cancer (melanoma) which has spread

Principal Investigator – SWOG S1400BCDI Protocol: Phase II/III Biomarker-driven Master protocol for 2nd line Therapy of Squamous cell lung CA

Principal Investigator – Amgen: randomized single blind study to estimate the effect of patient education on reported bone pain in BC patients receiving chemo & pegfilgrastim

Principal Investigator – Millennium C25003 Protocol: a randomized open label phase 3 trial of A+AVD vs ABVD as frontline therapy in pts with adv classic HL

Principal Investigator – Janssen PCI-32765DB Protocol: a randomized double blind placebo controlled phase 3 study of the BTK inhibitor Ibrutinib in combination with R-CHOP in subjects with newly diagnosed Non-GCB DLBCL

Principal Investigator – Synta 9090-14 Protocol: a randomized phase 3 study of ganetespib in combination with docetaxel vs docetaxel alone in pts with advanced NSCLC adenocarcinoma

Principal Investigator – Bavarian Nordic, Inc. BNIT-PRV-301 Protocol: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer

Principal Investigator – Dendron Corporation P10-3 Protocol: A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER

Principal Investigator – Astra Zeneca: A Multi-center, AZD9291 Expanded Access Program for the Treatment of Patients with Advanced/Metastatic EGFR T790M Mutation-Positive Non-small Cell Lung Cancer (NSCLC) Who Have Received Prior EGFR TKI Therapy

Principal Investigator – Pharmacyclics: A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton's Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma

Principal Investigator – Novartis: An Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer With No Prior Hormonal Therapy for Advanced Disease (NCT02941926). 2017

Principal Investigator – Pfizer Madeline: Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer. 2017

Curriculum Vitae
Justin P. Favaro, MD, PhD

Principal Investigator- Merrimack SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy. 2017

Principal Investigator – Pfizer Javelin: A Randomized, Double-Blind, Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. 2018

Principal Investigator – Ipsen: Lanreotide and Octreotide LAR for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis. 2018

Principal Investigator – ARMO Biosciences Cypress 1: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression. 2018

Principal Investigator – Veloce Biopharma: A Multi-centered, Randomized, Double-Blind, Vehicle-Controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of Topical Povidone-Iodine Nail Solution (VBP-926) for the Treatment of Chemotherapy-Associated Paronychia in Cancer Patients (NCT03207906). 2018

Principal Investigator – Incyte: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy. 2018

Principal Investigator – Amgen: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN. 2018

Principal Investigator – Amgen: An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers. 2018

Principal Investigator –Boehringer Ingelheim Pharmaceuticals, Inc: XENERA™-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease. 2018

Principal Investigator – Regeneron: Cemiplimab Survivorship Epidemiology (CASE) Study

Principal Investigator – Astrazeneca: An Open Label, Multi-center, IRESSA™ Clinical Access Program of Gefitinib 250 mg (IRESSA™) for the continued treatment of patients in the United States who are currently benefiting or have benefited from gefitinib treatment. 2019

Curriculum Vitae
Justin P. Favaro, MD, PhD

Principal Investigator – Incyte: Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207). 2019


Principal Investigator – Novocure: LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure

Principal Investigator – SecuraBio Inc: A Disease Registry Encompassing the Care of Patients with Multiple Myeloma on Panobinostat (RECOMM)


Principal Investigator – Daily Body Restore: A Double-blind, Placebo-controlled Evaluation of a Proprietary Dietary Supplement Containing Probiotics and Digestive Enzymes for Alleviating Chemotherapy-Associated Adverse Events in Colorectal Cancer

Principal Investigator – GSK: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.



Signature



Date

